{"id":"W4367602020","doi":"10.1158/1078-0432.ccr-22-2595","title":"Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nova Scotia Hospital; Université de Montréal; University of Calgary; MEG-3 (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Ovarian cancer; Clinical trial; Confidence interval; Phases of clinical research; Cyclophosphamide; Population; Progressive disease; Surgery; Cancer; Randomized controlled trial; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067285,0.0005286421,0.0006244271,0.0002193787,0.000174757,0.0003757675,0.0004077097,0.0005541204,0.002725951],"category_scores_gemma":[0.000809455,0.0001605428,0.0004636286,0.0002176864,0.0003116044,0.0002744,0.0001672842,0.001249833,0.0003544036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002902378,"about_ca_system_score_gemma":0.0005423896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002517435,"about_ca_topic_score_gemma":0.0008852358,"domain_scores_codex":[0.9997377,0.0001621959,0.00001692336,0.0000274105,0.00002902551,0.00002674159],"domain_scores_gemma":[0.9994938,0.0001451132,0.0001415231,0.00003649483,0.00002147355,0.0001615536],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5603931,0.02714075,0.02208432,0.002069185,0.001635951,0.0004390132,0.0002351717,0.002255036,0.05712793,0.0004552063,0.007031488,0.3191328],"study_design_scores_gemma":[0.5784549,0.3757523,0.02488583,0.00007785236,0.0006336663,0.0007264709,0.0000359096,0.001383442,0.01151893,0.0001692166,0.006341195,0.00002036618],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888912,0.006476091,0.0003842514,0.0004485153,0.00007184675,0.001021913,0.0005773678,0.00006804142,0.002060881],"genre_scores_gemma":[0.9898878,0.003087001,0.001149327,0.0005684316,0.0002070277,0.001195114,0.001856171,0.00001504041,0.002034132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002725951,"threshold_uncertainty_score":0.009119213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3419866632278414,"score_gpt":0.5729524062175213,"score_spread":0.2309657429896799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}